medigraphic.com
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon

2023, Number 1

<< Back Next >>

Rev Mex Coloproctol 2023; 19 (1)

Cytoreduction and transoperative hyperthermic chemotherapy in the management of colorectal cancer carcinomatosis: overview of current events

Londoño-Schimmer EE

Language: Spanish
References: 34
Page: 14-18
PDF size: 211.20 Kb.


ABSTRACT

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a therapeutic alternative for patients with peritoneal carcinomatosis from colorectal cancer. Patients should be evaluated by a multidisciplinary group dedicated to this specific illness to determine if they are candidates for the procedure. Constant high-level research will translate in better clinical results.


REFERENCES

  1. Stewart CL, Warner S, Ito K et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018; 55: 330-379.

  2. Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014; 2014: 782890.

  3. Massolou D, Benizri E, Chevallier A et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017; 213: 377-387.

  4. Hugen N, Van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Obcol. 2014; 25: 651-657.

  5. Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis pf colorectal origin: incidence and current treatment strategies. Ann Surg. 2006; 243: 212-222.

  6. Brierley J, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumours. 8th edition. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.

  7. Franko J, Shi Q, Goldman CD et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012; 30: 263-267.

  8. Levinson KL, Belinson JL. Peritoneal carcinomatosis: signs and symptoms. Advances in the management of peritoneal carcinomatosis. Future Medicine [Internet]. 2014. Available in: https://doi.org/10.2217/ebo.12.407

  9. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012; 99: 699-705.

  10. Jayne Dg, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2020; 89: 1545-1550.

  11. Willett C, Tepper JE, Cohen A, Orlow E, Welch C. Obstructive and perforative colonic carcinoma: patterns of failure. J Clin Oncol. 1985; 3: 379-384.

  12. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009; 16: 327-333.

  13. Dohan A, Hoeffel C, Soyer P, Jannot AS, Valette PJ, Thivolet A et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg. 2017; 104: 1244-1249.

  14. Chang MC, Chen JH, Liang JA, Huang WS, Cheng KY, Kao CH. PET or PT/CT for detection of peritoneal carcinomatosis: a meta-analysis. Clin Nucl Med. 2013; 38: 623-629.

  15. Kim SJ, Lee SW. Diagnostic accuracy of (18)F-FDG PET/CT for detection of peritoneal carcinomatosis; a systemic review and meta-analysis. Br J Radiol. 2018; 91: 20170519.

  16. Sugarbaker PH. Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg. 1995; 19: 235-240.

  17. Bhatt A, Goére D. Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal cancer. Indian J Surg Oncol. 2016; 7: 177-187.

  18. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221: 29-42.

  19. Esquivel J, Piso P, Verwaal V et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014; 110: 777-836.

  20. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21: 3737-3743.

  21. Association Française de Chirurgie, 2014. Presentación durante el 11 Congreso de la Peritoneal Surface Oncology Group International, Paris, Fr. 9-11 de Septiembre 2018.

  22. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15: 2426-2432.

  23. Mirmezani R, Mehta AM, Chandrakumaran K, Cecil T, Moran B et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014; 111: 1500-1508.

  24. Klaver CEL, Wisselink DD, Punt CJ et al. Adjuvant hyperthermic intraoperative chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicenter, open-label, randomized trial. Lancet Gastroenterol Hepatol. 2019; 4: 761-770.

  25. Goére D, Glehan O, Quénet F et al. Second-look surgery plus hyperthermic introperative chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): randomized, phase 3 study. Lancet Oncol. 2020; 21: 1147-1154.

  26. Moran B. PROPHYLOCHIP: no benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2020; 21: 1124-1125.

  27. Quénet F, Elias D, Rosa L et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGY 7): a multicenter randomized, open-label, phase 3 trial. Lancet Oncology. 2021; 22: 256-266.

  28. Rovers KP, Kok NFM, Punt CJA, Tanis PJ, de Hingh IHJT. Limitations of the PRODIGY 7 trial. Lancet Oncol. 2021; 22: e174.

  29. Cashin P. Limitations of PRODIGY 7 trial. Lancet Oncol. 2021; 22: e177.

  30. Quénet F, Roca L, de Forges H, Gléhen O, Goére D. Limitations of the PRODIGY 7 trial-Author's reply. Lancet Oncol. 2021; 22: e179-e180.

  31. Protocolo del Grupo de Cuidado Clínico de Neoplasias del Peritoneo, Departamento de Cirugía, Hospital Universitario Fundación Santa Fe de Bogotá. Certificación con Excelencia por la Joint Comision International, Diciembre 2021.

  32. Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressirized intraperitoneal aerosol chemotherapy with oxiloplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016; 18: 364-371.

  33. Alyami M, Hübner M, Grass F et al. Pressurised intraepithelial aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019; 20: e368-e377.

  34. Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. Eur J Surg Oncol. 2022; 48 (4): 789-794.




2020     |     www.medigraphic.com